Data from the CodeBreaK 100 NSCLC subset population prompted the FDA to grant sotorasib accelerated approval for patients with KRAS^G12C mutation–positive NSCLC. Read More ›

Sotorasib showed encouraging anticancer activity in phase 2 of a clinical trial of patients with heavily treated advanced NSCLC. Read More ›

Immunotherapy and targeted therapy have resulted in improved survival rates in patients with NSCLC over the past decade. Read More ›

Multidisciplinary tumor board members work closely to make the best clinical decisions for their patients with cancer to improve patient and institutional outcomes. Their decisions should be based on the clinical data of each patient in line with their own clinical and institutional guidelines. Read More ›

Recently released results using liquid biopsy shows KRAS G12C mutation in patients with NSCLC can be lost or acquired at progressive disease. Read More ›

Social listening can offer investigators valuable information about unmet patient needs and concerns regarding their cancer treatment and to direct future research. Read More ›

Researchers found a large underrepresentation gap among minority populations across major cancer types in clinical trials. Read More ›

Improved understanding of self-care behaviors in patients with cancer who take oral anticancer medications can help healthcare professionals support patient medication adherence. Read More ›

Dual EGFR targeting with amivantamab-vmjw (Rybrevant) plus lazertinib (Leclaza) led to durable responses in more than one-third of chemotherapy-naïve patients with EGFR-positive non–small-cell lung cancer (NSCLC) whose disease had progressed on osimertinib (Tagrisso) therapy, according to a cohort analysis of the CHRYSALIS trial, presented at the American Society of Clinical Oncology 2021 virtual annual meeting. Read More ›

A recently released MYLUNG study found that most patients with untreated metastatic NSCLC tested for ≥1 biomarkers, but <50% of patients had ≥5 biomarker tests. Read More ›